^
Association details:
| Biomarker: | VEGFA elevation |
|---|---|
| Cancer: | Glioblastoma |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + Avastin (bevacizumab) (VEGF-A inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Randomized phase II and biomarker study of pembrolizumab plus bevacizumab versus pembrolizumab alone for recurrent glioblastoma patients
Published date:
11/16/2020
Excerpt:
Eighty bevacizumab-naive, recurrent glioblastoma patients randomized to pembrolizumab with bevacizumab (cohort A, n=50) or pembrolizumab monotherapy (cohort B, n=30)….worsened OS correlated with baseline dexamethasone use and increased post-therapy plasma VEGF (cohort A)...
DOI:
10.1158/1078-0432.CCR-20-2500
